Post-Yervoy melanoma data at ESMO support BMS's Opdivo BLA
This article was originally published in Scrip
Bristol-Myers Squibb revealed Phase III results in melanoma for the programmed cell death-1 (PD-1) inhibitor Opdivo (nivolumab) at the European Society for Medical Oncology (ESMO) meeting on 29 September that support the biologic license application (BLA) for which the US FDA recently granted priority review – data that may outshine Merck & Co's competing drug.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.